Global Age Related Macular Degeneration Drugs Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The global Age Related Macular Degeneration Drugs market size is projected to grow from US$ 7557.7 million in 2023 to US$ 11450 million in 2030; it is expected to grow at a CAGR of 6.1% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Age Related Macular Degeneration Drugs Industry Forecast” looks at past sales and reviews total world Age Related Macular Degeneration Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Age Related Macular Degeneration Drugs sales for 2024 through 2030. With Age Related Macular Degeneration Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Age Related Macular Degeneration Drugs industry.
This Insight Report provides a comprehensive analysis of the global Age Related Macular Degeneration Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Age Related Macular Degeneration Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Age Related Macular Degeneration Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Age Related Macular Degeneration Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Age Related Macular Degeneration Drugs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Age Related Macular Degeneration Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
What is the 10-year outlook for the global Age Related Macular Degeneration Drugs market?
What factors are driving Age Related Macular Degeneration Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Age Related Macular Degeneration Drugs market opportunities vary by end market size?
How does Age Related Macular Degeneration Drugs break out type, application?
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
The global Age Related Macular Degeneration Drugs market size is projected to grow from US$ 7557.7 million in 2023 to US$ 11450 million in 2030; it is expected to grow at a CAGR of 6.1% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Age Related Macular Degeneration Drugs Industry Forecast” looks at past sales and reviews total world Age Related Macular Degeneration Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Age Related Macular Degeneration Drugs sales for 2024 through 2030. With Age Related Macular Degeneration Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Age Related Macular Degeneration Drugs industry.
This Insight Report provides a comprehensive analysis of the global Age Related Macular Degeneration Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Age Related Macular Degeneration Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Age Related Macular Degeneration Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Age Related Macular Degeneration Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Age Related Macular Degeneration Drugs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Age Related Macular Degeneration Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
- Lucentis
- Eylea
- Avastin
- Squalamine
- Conercept
- Lampalizamab
- Others
- 50-60 Years Old
- 60-70 Years Old
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Bayer Healthcare
- Roche
- Neurotech Pharmaceuticals
- Regeneron Pharmaceuticals
- Allergan
What is the 10-year outlook for the global Age Related Macular Degeneration Drugs market?
What factors are driving Age Related Macular Degeneration Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Age Related Macular Degeneration Drugs market opportunities vary by end market size?
How does Age Related Macular Degeneration Drugs break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Age Related Macular Degeneration Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Age Related Macular Degeneration Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Age Related Macular Degeneration Drugs by Country/Region, 2019, 2023 & 2030
2.2 Age Related Macular Degeneration Drugs Segment by Type
2.2.1 Lucentis
2.2.2 Eylea
2.2.3 Avastin
2.2.4 Squalamine
2.2.5 Conercept
2.2.6 Lampalizamab
2.2.7 Others
2.3 Age Related Macular Degeneration Drugs Sales by Type
2.3.1 Global Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Age Related Macular Degeneration Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Age Related Macular Degeneration Drugs Sale Price by Type (2019-2024)
2.4 Age Related Macular Degeneration Drugs Segment by Application
2.4.1 50-60 Years Old
2.4.2 60-70 Years Old
2.4.3 Others
2.5 Age Related Macular Degeneration Drugs Sales by Application
2.5.1 Global Age Related Macular Degeneration Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Age Related Macular Degeneration Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Age Related Macular Degeneration Drugs Sale Price by Application (2019-2024)
3 GLOBAL AGE RELATED MACULAR DEGENERATION DRUGS BY COMPANY
3.1 Global Age Related Macular Degeneration Drugs Breakdown Data by Company
3.1.1 Global Age Related Macular Degeneration Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Age Related Macular Degeneration Drugs Sales Market Share by Company (2019-2024)
3.2 Global Age Related Macular Degeneration Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Age Related Macular Degeneration Drugs Revenue by Company (2019-2024)
3.2.2 Global Age Related Macular Degeneration Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Age Related Macular Degeneration Drugs Sale Price by Company
3.4 Key Manufacturers Age Related Macular Degeneration Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Age Related Macular Degeneration Drugs Product Location Distribution
3.4.2 Players Age Related Macular Degeneration Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR AGE RELATED MACULAR DEGENERATION DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Age Related Macular Degeneration Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Age Related Macular Degeneration Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Age Related Macular Degeneration Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Age Related Macular Degeneration Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Age Related Macular Degeneration Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Age Related Macular Degeneration Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Age Related Macular Degeneration Drugs Sales Growth
4.4 APAC Age Related Macular Degeneration Drugs Sales Growth
4.5 Europe Age Related Macular Degeneration Drugs Sales Growth
4.6 Middle East & Africa Age Related Macular Degeneration Drugs Sales Growth
5 AMERICAS
5.1 Americas Age Related Macular Degeneration Drugs Sales by Country
5.1.1 Americas Age Related Macular Degeneration Drugs Sales by Country (2019-2024)
5.1.2 Americas Age Related Macular Degeneration Drugs Revenue by Country (2019-2024)
5.2 Americas Age Related Macular Degeneration Drugs Sales by Type
5.3 Americas Age Related Macular Degeneration Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Age Related Macular Degeneration Drugs Sales by Region
6.1.1 APAC Age Related Macular Degeneration Drugs Sales by Region (2019-2024)
6.1.2 APAC Age Related Macular Degeneration Drugs Revenue by Region (2019-2024)
6.2 APAC Age Related Macular Degeneration Drugs Sales by Type
6.3 APAC Age Related Macular Degeneration Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Age Related Macular Degeneration Drugs by Country
7.1.1 Europe Age Related Macular Degeneration Drugs Sales by Country (2019-2024)
7.1.2 Europe Age Related Macular Degeneration Drugs Revenue by Country (2019-2024)
7.2 Europe Age Related Macular Degeneration Drugs Sales by Type
7.3 Europe Age Related Macular Degeneration Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Age Related Macular Degeneration Drugs by Country
8.1.1 Middle East & Africa Age Related Macular Degeneration Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Age Related Macular Degeneration Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Age Related Macular Degeneration Drugs Sales by Type
8.3 Middle East & Africa Age Related Macular Degeneration Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Age Related Macular Degeneration Drugs
10.3 Manufacturing Process Analysis of Age Related Macular Degeneration Drugs
10.4 Industry Chain Structure of Age Related Macular Degeneration Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Age Related Macular Degeneration Drugs Distributors
11.3 Age Related Macular Degeneration Drugs Customer
12 WORLD FORECAST REVIEW FOR AGE RELATED MACULAR DEGENERATION DRUGS BY GEOGRAPHIC REGION
12.1 Global Age Related Macular Degeneration Drugs Market Size Forecast by Region
12.1.1 Global Age Related Macular Degeneration Drugs Forecast by Region (2025-2030)
12.1.2 Global Age Related Macular Degeneration Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Age Related Macular Degeneration Drugs Forecast by Type
12.7 Global Age Related Macular Degeneration Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.1.3 Novartis Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Bayer Healthcare
13.2.1 Bayer Healthcare Company Information
13.2.2 Bayer Healthcare Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.2.3 Bayer Healthcare Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bayer Healthcare Main Business Overview
13.2.5 Bayer Healthcare Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.3.3 Roche Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Neurotech Pharmaceuticals
13.4.1 Neurotech Pharmaceuticals Company Information
13.4.2 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.4.3 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Neurotech Pharmaceuticals Main Business Overview
13.4.5 Neurotech Pharmaceuticals Latest Developments
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Information
13.5.2 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.5.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Regeneron Pharmaceuticals Main Business Overview
13.5.5 Regeneron Pharmaceuticals Latest Developments
13.6 Allergan
13.6.1 Allergan Company Information
13.6.2 Allergan Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.6.3 Allergan Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Allergan Main Business Overview
13.6.5 Allergan Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Age Related Macular Degeneration Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Age Related Macular Degeneration Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Age Related Macular Degeneration Drugs by Country/Region, 2019, 2023 & 2030
2.2 Age Related Macular Degeneration Drugs Segment by Type
2.2.1 Lucentis
2.2.2 Eylea
2.2.3 Avastin
2.2.4 Squalamine
2.2.5 Conercept
2.2.6 Lampalizamab
2.2.7 Others
2.3 Age Related Macular Degeneration Drugs Sales by Type
2.3.1 Global Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Age Related Macular Degeneration Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Age Related Macular Degeneration Drugs Sale Price by Type (2019-2024)
2.4 Age Related Macular Degeneration Drugs Segment by Application
2.4.1 50-60 Years Old
2.4.2 60-70 Years Old
2.4.3 Others
2.5 Age Related Macular Degeneration Drugs Sales by Application
2.5.1 Global Age Related Macular Degeneration Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Age Related Macular Degeneration Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Age Related Macular Degeneration Drugs Sale Price by Application (2019-2024)
3 GLOBAL AGE RELATED MACULAR DEGENERATION DRUGS BY COMPANY
3.1 Global Age Related Macular Degeneration Drugs Breakdown Data by Company
3.1.1 Global Age Related Macular Degeneration Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Age Related Macular Degeneration Drugs Sales Market Share by Company (2019-2024)
3.2 Global Age Related Macular Degeneration Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Age Related Macular Degeneration Drugs Revenue by Company (2019-2024)
3.2.2 Global Age Related Macular Degeneration Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Age Related Macular Degeneration Drugs Sale Price by Company
3.4 Key Manufacturers Age Related Macular Degeneration Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Age Related Macular Degeneration Drugs Product Location Distribution
3.4.2 Players Age Related Macular Degeneration Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR AGE RELATED MACULAR DEGENERATION DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Age Related Macular Degeneration Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Age Related Macular Degeneration Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Age Related Macular Degeneration Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Age Related Macular Degeneration Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Age Related Macular Degeneration Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Age Related Macular Degeneration Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Age Related Macular Degeneration Drugs Sales Growth
4.4 APAC Age Related Macular Degeneration Drugs Sales Growth
4.5 Europe Age Related Macular Degeneration Drugs Sales Growth
4.6 Middle East & Africa Age Related Macular Degeneration Drugs Sales Growth
5 AMERICAS
5.1 Americas Age Related Macular Degeneration Drugs Sales by Country
5.1.1 Americas Age Related Macular Degeneration Drugs Sales by Country (2019-2024)
5.1.2 Americas Age Related Macular Degeneration Drugs Revenue by Country (2019-2024)
5.2 Americas Age Related Macular Degeneration Drugs Sales by Type
5.3 Americas Age Related Macular Degeneration Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Age Related Macular Degeneration Drugs Sales by Region
6.1.1 APAC Age Related Macular Degeneration Drugs Sales by Region (2019-2024)
6.1.2 APAC Age Related Macular Degeneration Drugs Revenue by Region (2019-2024)
6.2 APAC Age Related Macular Degeneration Drugs Sales by Type
6.3 APAC Age Related Macular Degeneration Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Age Related Macular Degeneration Drugs by Country
7.1.1 Europe Age Related Macular Degeneration Drugs Sales by Country (2019-2024)
7.1.2 Europe Age Related Macular Degeneration Drugs Revenue by Country (2019-2024)
7.2 Europe Age Related Macular Degeneration Drugs Sales by Type
7.3 Europe Age Related Macular Degeneration Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Age Related Macular Degeneration Drugs by Country
8.1.1 Middle East & Africa Age Related Macular Degeneration Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Age Related Macular Degeneration Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Age Related Macular Degeneration Drugs Sales by Type
8.3 Middle East & Africa Age Related Macular Degeneration Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Age Related Macular Degeneration Drugs
10.3 Manufacturing Process Analysis of Age Related Macular Degeneration Drugs
10.4 Industry Chain Structure of Age Related Macular Degeneration Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Age Related Macular Degeneration Drugs Distributors
11.3 Age Related Macular Degeneration Drugs Customer
12 WORLD FORECAST REVIEW FOR AGE RELATED MACULAR DEGENERATION DRUGS BY GEOGRAPHIC REGION
12.1 Global Age Related Macular Degeneration Drugs Market Size Forecast by Region
12.1.1 Global Age Related Macular Degeneration Drugs Forecast by Region (2025-2030)
12.1.2 Global Age Related Macular Degeneration Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Age Related Macular Degeneration Drugs Forecast by Type
12.7 Global Age Related Macular Degeneration Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.1.3 Novartis Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Bayer Healthcare
13.2.1 Bayer Healthcare Company Information
13.2.2 Bayer Healthcare Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.2.3 Bayer Healthcare Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bayer Healthcare Main Business Overview
13.2.5 Bayer Healthcare Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.3.3 Roche Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Neurotech Pharmaceuticals
13.4.1 Neurotech Pharmaceuticals Company Information
13.4.2 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.4.3 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Neurotech Pharmaceuticals Main Business Overview
13.4.5 Neurotech Pharmaceuticals Latest Developments
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Information
13.5.2 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.5.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Regeneron Pharmaceuticals Main Business Overview
13.5.5 Regeneron Pharmaceuticals Latest Developments
13.6 Allergan
13.6.1 Allergan Company Information
13.6.2 Allergan Age Related Macular Degeneration Drugs Product Portfolios and Specifications
13.6.3 Allergan Age Related Macular Degeneration Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Allergan Main Business Overview
13.6.5 Allergan Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Age Related Macular Degeneration Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Age Related Macular Degeneration Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Lucentis
Table 4. Major Players of Eylea
Table 5. Major Players of Avastin
Table 6. Major Players of Squalamine
Table 7. Major Players of Conercept
Table 8. Major Players of Lampalizamab
Table 9. Major Players of Others
Table 10. Global Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 11. Global Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Table 12. Global Age Related Macular Degeneration Drugs Revenue by Type (2019-2024) & ($ million)
Table 13. Global Age Related Macular Degeneration Drugs Revenue Market Share by Type (2019-2024)
Table 14. Global Age Related Macular Degeneration Drugs Sale Price by Type (2019-2024) & (USD/MT)
Table 15. Global Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 16. Global Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Table 17. Global Age Related Macular Degeneration Drugs Revenue by Application (2019-2024)
Table 18. Global Age Related Macular Degeneration Drugs Revenue Market Share by Application (2019-2024)
Table 19. Global Age Related Macular Degeneration Drugs Sale Price by Application (2019-2024) & (USD/MT)
Table 20. Global Age Related Macular Degeneration Drugs Sales by Company (2019-2024) & (K MT)
Table 21. Global Age Related Macular Degeneration Drugs Sales Market Share by Company (2019-2024)
Table 22. Global Age Related Macular Degeneration Drugs Revenue by Company (2019-2024) ($ Millions)
Table 23. Global Age Related Macular Degeneration Drugs Revenue Market Share by Company (2019-2024)
Table 24. Global Age Related Macular Degeneration Drugs Sale Price by Company (2019-2024) & (USD/MT)
Table 25. Key Manufacturers Age Related Macular Degeneration Drugs Producing Area Distribution and Sales Area
Table 26. Players Age Related Macular Degeneration Drugs Products Offered
Table 27. Age Related Macular Degeneration Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Age Related Macular Degeneration Drugs Sales by Geographic Region (2019-2024) & (K MT)
Table 31. Global Age Related Macular Degeneration Drugs Sales Market Share Geographic Region (2019-2024)
Table 32. Global Age Related Macular Degeneration Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 33. Global Age Related Macular Degeneration Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 34. Global Age Related Macular Degeneration Drugs Sales by Country/Region (2019-2024) & (K MT)
Table 35. Global Age Related Macular Degeneration Drugs Sales Market Share by Country/Region (2019-2024)
Table 36. Global Age Related Macular Degeneration Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 37. Global Age Related Macular Degeneration Drugs Revenue Market Share by Country/Region (2019-2024)
Table 38. Americas Age Related Macular Degeneration Drugs Sales by Country (2019-2024) & (K MT)
Table 39. Americas Age Related Macular Degeneration Drugs Sales Market Share by Country (2019-2024)
Table 40. Americas Age Related Macular Degeneration Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 41. Americas Age Related Macular Degeneration Drugs Revenue Market Share by Country (2019-2024)
Table 42. Americas Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 43. Americas Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 44. APAC Age Related Macular Degeneration Drugs Sales by Region (2019-2024) & (K MT)
Table 45. APAC Age Related Macular Degeneration Drugs Sales Market Share by Region (2019-2024)
Table 46. APAC Age Related Macular Degeneration Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 47. APAC Age Related Macular Degeneration Drugs Revenue Market Share by Region (2019-2024)
Table 48. APAC Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 49. APAC Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 50. Europe Age Related Macular Degeneration Drugs Sales by Country (2019-2024) & (K MT)
Table 51. Europe Age Related Macular Degeneration Drugs Sales Market Share by Country (2019-2024)
Table 52. Europe Age Related Macular Degeneration Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 53. Europe Age Related Macular Degeneration Drugs Revenue Market Share by Country (2019-2024)
Table 54. Europe Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 55. Europe Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 56. Middle East & Africa Age Related Macular Degeneration Drugs Sales by Country (2019-2024) & (K MT)
Table 57. Middle East & Africa Age Related Macular Degeneration Drugs Sales Market Share by Country (2019-2024)
Table 58. Middle East & Africa Age Related Macular Degeneration Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 59. Middle East & Africa Age Related Macular Degeneration Drugs Revenue Market Share by Country (2019-2024)
Table 60. Middle East & Africa Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 61. Middle East & Africa Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 62. Key Market Drivers & Growth Opportunities of Age Related Macular Degeneration Drugs
Table 63. Key Market Challenges & Risks of Age Related Macular Degeneration Drugs
Table 64. Key Industry Trends of Age Related Macular Degeneration Drugs
Table 65. Age Related Macular Degeneration Drugs Raw Material
Table 66. Key Suppliers of Raw Materials
Table 67. Age Related Macular Degeneration Drugs Distributors List
Table 68. Age Related Macular Degeneration Drugs Customer List
Table 69. Global Age Related Macular Degeneration Drugs Sales Forecast by Region (2025-2030) & (K MT)
Table 70. Global Age Related Macular Degeneration Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Americas Age Related Macular Degeneration Drugs Sales Forecast by Country (2025-2030) & (K MT)
Table 72. Americas Age Related Macular Degeneration Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. APAC Age Related Macular Degeneration Drugs Sales Forecast by Region (2025-2030) & (K MT)
Table 74. APAC Age Related Macular Degeneration Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 75. Europe Age Related Macular Degeneration Drugs Sales Forecast by Country (2025-2030) & (K MT)
Table 76. Europe Age Related Macular Degeneration Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 77. Middle East & Africa Age Related Macular Degeneration Drugs Sales Forecast by Country (2025-2030) & (K MT)
Table 78. Middle East & Africa Age Related Macular Degeneration Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 79. Global Age Related Macular Degeneration Drugs Sales Forecast by Type (2025-2030) & (K MT)
Table 80. Global Age Related Macular Degeneration Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 81. Global Age Related Macular Degeneration Drugs Sales Forecast by Application (2025-2030) & (K MT)
Table 82. Global Age Related Macular Degeneration Drugs Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 83. Novartis Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Novartis Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 85. Novartis Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 86. Novartis Main Business
Table 87. Novartis Latest Developments
Table 88. Bayer Healthcare Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Bayer Healthcare Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 90. Bayer Healthcare Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 91. Bayer Healthcare Main Business
Table 92. Bayer Healthcare Latest Developments
Table 93. Roche Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Roche Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 95. Roche Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 96. Roche Main Business
Table 97. Roche Latest Developments
Table 98. Neurotech Pharmaceuticals Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 100. Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 101. Neurotech Pharmaceuticals Main Business
Table 102. Neurotech Pharmaceuticals Latest Developments
Table 103. Regeneron Pharmaceuticals Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 105. Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 106. Regeneron Pharmaceuticals Main Business
Table 107. Regeneron Pharmaceuticals Latest Developments
Table 108. Allergan Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Allergan Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 110. Allergan Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 111. Allergan Main Business
Table 112. Allergan Latest Developments
Table 1. Age Related Macular Degeneration Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Age Related Macular Degeneration Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Lucentis
Table 4. Major Players of Eylea
Table 5. Major Players of Avastin
Table 6. Major Players of Squalamine
Table 7. Major Players of Conercept
Table 8. Major Players of Lampalizamab
Table 9. Major Players of Others
Table 10. Global Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 11. Global Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Table 12. Global Age Related Macular Degeneration Drugs Revenue by Type (2019-2024) & ($ million)
Table 13. Global Age Related Macular Degeneration Drugs Revenue Market Share by Type (2019-2024)
Table 14. Global Age Related Macular Degeneration Drugs Sale Price by Type (2019-2024) & (USD/MT)
Table 15. Global Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 16. Global Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Table 17. Global Age Related Macular Degeneration Drugs Revenue by Application (2019-2024)
Table 18. Global Age Related Macular Degeneration Drugs Revenue Market Share by Application (2019-2024)
Table 19. Global Age Related Macular Degeneration Drugs Sale Price by Application (2019-2024) & (USD/MT)
Table 20. Global Age Related Macular Degeneration Drugs Sales by Company (2019-2024) & (K MT)
Table 21. Global Age Related Macular Degeneration Drugs Sales Market Share by Company (2019-2024)
Table 22. Global Age Related Macular Degeneration Drugs Revenue by Company (2019-2024) ($ Millions)
Table 23. Global Age Related Macular Degeneration Drugs Revenue Market Share by Company (2019-2024)
Table 24. Global Age Related Macular Degeneration Drugs Sale Price by Company (2019-2024) & (USD/MT)
Table 25. Key Manufacturers Age Related Macular Degeneration Drugs Producing Area Distribution and Sales Area
Table 26. Players Age Related Macular Degeneration Drugs Products Offered
Table 27. Age Related Macular Degeneration Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Age Related Macular Degeneration Drugs Sales by Geographic Region (2019-2024) & (K MT)
Table 31. Global Age Related Macular Degeneration Drugs Sales Market Share Geographic Region (2019-2024)
Table 32. Global Age Related Macular Degeneration Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 33. Global Age Related Macular Degeneration Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 34. Global Age Related Macular Degeneration Drugs Sales by Country/Region (2019-2024) & (K MT)
Table 35. Global Age Related Macular Degeneration Drugs Sales Market Share by Country/Region (2019-2024)
Table 36. Global Age Related Macular Degeneration Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 37. Global Age Related Macular Degeneration Drugs Revenue Market Share by Country/Region (2019-2024)
Table 38. Americas Age Related Macular Degeneration Drugs Sales by Country (2019-2024) & (K MT)
Table 39. Americas Age Related Macular Degeneration Drugs Sales Market Share by Country (2019-2024)
Table 40. Americas Age Related Macular Degeneration Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 41. Americas Age Related Macular Degeneration Drugs Revenue Market Share by Country (2019-2024)
Table 42. Americas Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 43. Americas Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 44. APAC Age Related Macular Degeneration Drugs Sales by Region (2019-2024) & (K MT)
Table 45. APAC Age Related Macular Degeneration Drugs Sales Market Share by Region (2019-2024)
Table 46. APAC Age Related Macular Degeneration Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 47. APAC Age Related Macular Degeneration Drugs Revenue Market Share by Region (2019-2024)
Table 48. APAC Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 49. APAC Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 50. Europe Age Related Macular Degeneration Drugs Sales by Country (2019-2024) & (K MT)
Table 51. Europe Age Related Macular Degeneration Drugs Sales Market Share by Country (2019-2024)
Table 52. Europe Age Related Macular Degeneration Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 53. Europe Age Related Macular Degeneration Drugs Revenue Market Share by Country (2019-2024)
Table 54. Europe Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 55. Europe Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 56. Middle East & Africa Age Related Macular Degeneration Drugs Sales by Country (2019-2024) & (K MT)
Table 57. Middle East & Africa Age Related Macular Degeneration Drugs Sales Market Share by Country (2019-2024)
Table 58. Middle East & Africa Age Related Macular Degeneration Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 59. Middle East & Africa Age Related Macular Degeneration Drugs Revenue Market Share by Country (2019-2024)
Table 60. Middle East & Africa Age Related Macular Degeneration Drugs Sales by Type (2019-2024) & (K MT)
Table 61. Middle East & Africa Age Related Macular Degeneration Drugs Sales by Application (2019-2024) & (K MT)
Table 62. Key Market Drivers & Growth Opportunities of Age Related Macular Degeneration Drugs
Table 63. Key Market Challenges & Risks of Age Related Macular Degeneration Drugs
Table 64. Key Industry Trends of Age Related Macular Degeneration Drugs
Table 65. Age Related Macular Degeneration Drugs Raw Material
Table 66. Key Suppliers of Raw Materials
Table 67. Age Related Macular Degeneration Drugs Distributors List
Table 68. Age Related Macular Degeneration Drugs Customer List
Table 69. Global Age Related Macular Degeneration Drugs Sales Forecast by Region (2025-2030) & (K MT)
Table 70. Global Age Related Macular Degeneration Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Americas Age Related Macular Degeneration Drugs Sales Forecast by Country (2025-2030) & (K MT)
Table 72. Americas Age Related Macular Degeneration Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. APAC Age Related Macular Degeneration Drugs Sales Forecast by Region (2025-2030) & (K MT)
Table 74. APAC Age Related Macular Degeneration Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 75. Europe Age Related Macular Degeneration Drugs Sales Forecast by Country (2025-2030) & (K MT)
Table 76. Europe Age Related Macular Degeneration Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 77. Middle East & Africa Age Related Macular Degeneration Drugs Sales Forecast by Country (2025-2030) & (K MT)
Table 78. Middle East & Africa Age Related Macular Degeneration Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 79. Global Age Related Macular Degeneration Drugs Sales Forecast by Type (2025-2030) & (K MT)
Table 80. Global Age Related Macular Degeneration Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 81. Global Age Related Macular Degeneration Drugs Sales Forecast by Application (2025-2030) & (K MT)
Table 82. Global Age Related Macular Degeneration Drugs Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 83. Novartis Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Novartis Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 85. Novartis Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 86. Novartis Main Business
Table 87. Novartis Latest Developments
Table 88. Bayer Healthcare Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Bayer Healthcare Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 90. Bayer Healthcare Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 91. Bayer Healthcare Main Business
Table 92. Bayer Healthcare Latest Developments
Table 93. Roche Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Roche Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 95. Roche Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 96. Roche Main Business
Table 97. Roche Latest Developments
Table 98. Neurotech Pharmaceuticals Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 100. Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 101. Neurotech Pharmaceuticals Main Business
Table 102. Neurotech Pharmaceuticals Latest Developments
Table 103. Regeneron Pharmaceuticals Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 105. Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 106. Regeneron Pharmaceuticals Main Business
Table 107. Regeneron Pharmaceuticals Latest Developments
Table 108. Allergan Basic Information, Age Related Macular Degeneration Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Allergan Age Related Macular Degeneration Drugs Product Portfolios and Specifications
Table 110. Allergan Age Related Macular Degeneration Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 111. Allergan Main Business
Table 112. Allergan Latest Developments
LIST OF FIGURES
Figure 1. Picture of Age Related Macular Degeneration Drugs
Figure 2. Age Related Macular Degeneration Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Age Related Macular Degeneration Drugs Sales Growth Rate 2019-2030 (K MT)
Figure 7. Global Age Related Macular Degeneration Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Age Related Macular Degeneration Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Lucentis
Figure 10. Product Picture of Eylea
Figure 11. Product Picture of Avastin
Figure 12. Product Picture of Squalamine
Figure 13. Product Picture of Conercept
Figure 14. Product Picture of Lampalizamab
Figure 15. Product Picture of Others
Figure 16. Global Age Related Macular Degeneration Drugs Sales Market Share by Type in 2023
Figure 17. Global Age Related Macular Degeneration Drugs Revenue Market Share by Type (2019-2024)
Figure 18. Age Related Macular Degeneration Drugs Consumed in 50-60 Years Old
Figure 19. Global Age Related Macular Degeneration Drugs Market: 50-60 Years Old (2019-2024) & (K MT)
Figure 20. Age Related Macular Degeneration Drugs Consumed in 60-70 Years Old
Figure 21. Global Age Related Macular Degeneration Drugs Market: 60-70 Years Old (2019-2024) & (K MT)
Figure 22. Age Related Macular Degeneration Drugs Consumed in Others
Figure 23. Global Age Related Macular Degeneration Drugs Market: Others (2019-2024) & (K MT)
Figure 24. Global Age Related Macular Degeneration Drugs Sales Market Share by Application (2023)
Figure 25. Global Age Related Macular Degeneration Drugs Revenue Market Share by Application in 2023
Figure 26. Age Related Macular Degeneration Drugs Sales Market by Company in 2023 (K MT)
Figure 27. Global Age Related Macular Degeneration Drugs Sales Market Share by Company in 2023
Figure 28. Age Related Macular Degeneration Drugs Revenue Market by Company in 2023 ($ Million)
Figure 29. Global Age Related Macular Degeneration Drugs Revenue Market Share by Company in 2023
Figure 30. Global Age Related Macular Degeneration Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 31. Global Age Related Macular Degeneration Drugs Revenue Market Share by Geographic Region in 2023
Figure 32. Americas Age Related Macular Degeneration Drugs Sales 2019-2024 (K MT)
Figure 33. Americas Age Related Macular Degeneration Drugs Revenue 2019-2024 ($ Millions)
Figure 34. APAC Age Related Macular Degeneration Drugs Sales 2019-2024 (K MT)
Figure 35. APAC Age Related Macular Degeneration Drugs Revenue 2019-2024 ($ Millions)
Figure 36. Europe Age Related Macular Degeneration Drugs Sales 2019-2024 (K MT)
Figure 37. Europe Age Related Macular Degeneration Drugs Revenue 2019-2024 ($ Millions)
Figure 38. Middle East & Africa Age Related Macular Degeneration Drugs Sales 2019-2024 (K MT)
Figure 39. Middle East & Africa Age Related Macular Degeneration Drugs Revenue 2019-2024 ($ Millions)
Figure 40. Americas Age Related Macular Degeneration Drugs Sales Market Share by Country in 2023
Figure 41. Americas Age Related Macular Degeneration Drugs Revenue Market Share by Country in 2023
Figure 42. Americas Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Figure 43. Americas Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Figure 44. United States Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 45. Canada Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 46. Mexico Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 47. Brazil Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 48. APAC Age Related Macular Degeneration Drugs Sales Market Share by Region in 2023
Figure 49. APAC Age Related Macular Degeneration Drugs Revenue Market Share by Regions in 2023
Figure 50. APAC Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Figure 51. APAC Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Figure 52. China Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 53. Japan Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 54. South Korea Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 55. Southeast Asia Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 56. India Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 57. Australia Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 58. China Taiwan Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 59. Europe Age Related Macular Degeneration Drugs Sales Market Share by Country in 2023
Figure 60. Europe Age Related Macular Degeneration Drugs Revenue Market Share by Country in 2023
Figure 61. Europe Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Figure 62. Europe Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Figure 63. Germany Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 64. France Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 65. UK Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 66. Italy Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 67. Russia Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 68. Middle East & Africa Age Related Macular Degeneration Drugs Sales Market Share by Country in 2023
Figure 69. Middle East & Africa Age Related Macular Degeneration Drugs Revenue Market Share by Country in 2023
Figure 70. Middle East & Africa Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Figure 71. Middle East & Africa Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Figure 72. Egypt Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 73. South Africa Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 74. Israel Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 75. Turkey Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 76. GCC Country Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 77. Manufacturing Cost Structure Analysis of Age Related Macular Degeneration Drugs in 2023
Figure 78. Manufacturing Process Analysis of Age Related Macular Degeneration Drugs
Figure 79. Industry Chain Structure of Age Related Macular Degeneration Drugs
Figure 80. Channels of Distribution
Figure 81. Global Age Related Macular Degeneration Drugs Sales Market Forecast by Region (2025-2030)
Figure 82. Global Age Related Macular Degeneration Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 83. Global Age Related Macular Degeneration Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 84. Global Age Related Macular Degeneration Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 85. Global Age Related Macular Degeneration Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 86. Global Age Related Macular Degeneration Drugs Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Age Related Macular Degeneration Drugs
Figure 2. Age Related Macular Degeneration Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Age Related Macular Degeneration Drugs Sales Growth Rate 2019-2030 (K MT)
Figure 7. Global Age Related Macular Degeneration Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Age Related Macular Degeneration Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Lucentis
Figure 10. Product Picture of Eylea
Figure 11. Product Picture of Avastin
Figure 12. Product Picture of Squalamine
Figure 13. Product Picture of Conercept
Figure 14. Product Picture of Lampalizamab
Figure 15. Product Picture of Others
Figure 16. Global Age Related Macular Degeneration Drugs Sales Market Share by Type in 2023
Figure 17. Global Age Related Macular Degeneration Drugs Revenue Market Share by Type (2019-2024)
Figure 18. Age Related Macular Degeneration Drugs Consumed in 50-60 Years Old
Figure 19. Global Age Related Macular Degeneration Drugs Market: 50-60 Years Old (2019-2024) & (K MT)
Figure 20. Age Related Macular Degeneration Drugs Consumed in 60-70 Years Old
Figure 21. Global Age Related Macular Degeneration Drugs Market: 60-70 Years Old (2019-2024) & (K MT)
Figure 22. Age Related Macular Degeneration Drugs Consumed in Others
Figure 23. Global Age Related Macular Degeneration Drugs Market: Others (2019-2024) & (K MT)
Figure 24. Global Age Related Macular Degeneration Drugs Sales Market Share by Application (2023)
Figure 25. Global Age Related Macular Degeneration Drugs Revenue Market Share by Application in 2023
Figure 26. Age Related Macular Degeneration Drugs Sales Market by Company in 2023 (K MT)
Figure 27. Global Age Related Macular Degeneration Drugs Sales Market Share by Company in 2023
Figure 28. Age Related Macular Degeneration Drugs Revenue Market by Company in 2023 ($ Million)
Figure 29. Global Age Related Macular Degeneration Drugs Revenue Market Share by Company in 2023
Figure 30. Global Age Related Macular Degeneration Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 31. Global Age Related Macular Degeneration Drugs Revenue Market Share by Geographic Region in 2023
Figure 32. Americas Age Related Macular Degeneration Drugs Sales 2019-2024 (K MT)
Figure 33. Americas Age Related Macular Degeneration Drugs Revenue 2019-2024 ($ Millions)
Figure 34. APAC Age Related Macular Degeneration Drugs Sales 2019-2024 (K MT)
Figure 35. APAC Age Related Macular Degeneration Drugs Revenue 2019-2024 ($ Millions)
Figure 36. Europe Age Related Macular Degeneration Drugs Sales 2019-2024 (K MT)
Figure 37. Europe Age Related Macular Degeneration Drugs Revenue 2019-2024 ($ Millions)
Figure 38. Middle East & Africa Age Related Macular Degeneration Drugs Sales 2019-2024 (K MT)
Figure 39. Middle East & Africa Age Related Macular Degeneration Drugs Revenue 2019-2024 ($ Millions)
Figure 40. Americas Age Related Macular Degeneration Drugs Sales Market Share by Country in 2023
Figure 41. Americas Age Related Macular Degeneration Drugs Revenue Market Share by Country in 2023
Figure 42. Americas Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Figure 43. Americas Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Figure 44. United States Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 45. Canada Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 46. Mexico Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 47. Brazil Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 48. APAC Age Related Macular Degeneration Drugs Sales Market Share by Region in 2023
Figure 49. APAC Age Related Macular Degeneration Drugs Revenue Market Share by Regions in 2023
Figure 50. APAC Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Figure 51. APAC Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Figure 52. China Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 53. Japan Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 54. South Korea Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 55. Southeast Asia Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 56. India Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 57. Australia Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 58. China Taiwan Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 59. Europe Age Related Macular Degeneration Drugs Sales Market Share by Country in 2023
Figure 60. Europe Age Related Macular Degeneration Drugs Revenue Market Share by Country in 2023
Figure 61. Europe Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Figure 62. Europe Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Figure 63. Germany Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 64. France Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 65. UK Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 66. Italy Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 67. Russia Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 68. Middle East & Africa Age Related Macular Degeneration Drugs Sales Market Share by Country in 2023
Figure 69. Middle East & Africa Age Related Macular Degeneration Drugs Revenue Market Share by Country in 2023
Figure 70. Middle East & Africa Age Related Macular Degeneration Drugs Sales Market Share by Type (2019-2024)
Figure 71. Middle East & Africa Age Related Macular Degeneration Drugs Sales Market Share by Application (2019-2024)
Figure 72. Egypt Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 73. South Africa Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 74. Israel Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 75. Turkey Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 76. GCC Country Age Related Macular Degeneration Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 77. Manufacturing Cost Structure Analysis of Age Related Macular Degeneration Drugs in 2023
Figure 78. Manufacturing Process Analysis of Age Related Macular Degeneration Drugs
Figure 79. Industry Chain Structure of Age Related Macular Degeneration Drugs
Figure 80. Channels of Distribution
Figure 81. Global Age Related Macular Degeneration Drugs Sales Market Forecast by Region (2025-2030)
Figure 82. Global Age Related Macular Degeneration Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 83. Global Age Related Macular Degeneration Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 84. Global Age Related Macular Degeneration Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 85. Global Age Related Macular Degeneration Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 86. Global Age Related Macular Degeneration Drugs Revenue Market Share Forecast by Application (2025-2030)
